Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 37

1.

Therapeutic approaches in myelofibrosis and myelodysplastic/myeloproliferative overlap syndromes.

Sochacki AL, Fischer MA, Savona MR.

Onco Targets Ther. 2016 Apr 15;9:2273-86. doi: 10.2147/OTT.S83868. eCollection 2016. Review.

2.

Diagnosis and Management of Polycythemia Vera: Proceedings from a Multidisciplinary Roundtable.

Raedler LA.

Am Health Drug Benefits. 2014 Oct;7(7 Suppl 3):S36-47. No abstract available.

3.

Gene Expression Profiling and Pathway Network Analysis Predicts a Novel Antitumor Function for a Botanical-Derived Drug, PG2.

Kuo YL, Chen CH, Chuang TH, Hua WK, Lin WJ, Hsu WH, Chang PM, Hsu SL, Huang TH, Kao CY, Huang CY.

Evid Based Complement Alternat Med. 2015;2015:917345. doi: 10.1155/2015/917345. Epub 2015 Apr 20.

4.

Transformation of an Unclassified Myeloproliferative Neoplasm with a Rare BCR-JAK2 Fusion Transcript Resulting from the Translocation (9;22)(p24;q11).

Chamseddine AN, Etancelin P, Penther D, Parmentier F, Kuadjovi C, Camus V, Contentin N, Lenain P, Bastard C, Tilly H, Jardin F.

Case Rep Hematol. 2015;2015:252537. doi: 10.1155/2015/252537. Epub 2015 Feb 18.

5.

Pulmonary arterial hypertension exacerbated by ruxolitinib.

Low AT, Howard L, Harrison C, Tulloh RM.

Haematologica. 2015 Jun;100(6):e244-5. doi: 10.3324/haematol.2014.120816. Epub 2015 Feb 14. No abstract available.

6.

Dual Aurora A and JAK2 kinase blockade effectively suppresses malignant transformation.

Yang H, Lawrence HR, Kazi A, Gevariya H, Patel R, Luo Y, Rix U, Schonbrunn E, Lawrence NJ, Sebti SM.

Oncotarget. 2014 May 30;5(10):2947-61.

7.

Pharmacophore and Virtual Screening of JAK3 inhibitors.

Rajeswari M, Santhi N, Bhuvaneswari V.

Bioinformation. 2014 Mar 19;10(3):157-63. doi: 10.6026/97320630010157. eCollection 2014.

8.

Interim analysis of safety and efficacy of ruxolitinib in patients with myelofibrosis and low platelet counts.

Talpaz M, Paquette R, Afrin L, Hamburg SI, Prchal JT, Jamieson K, Terebelo HR, Ortega GL, Lyons RM, Tiu RV, Winton EF, Natrajan K, Odenike O, Claxton D, Peng W, O'Neill P, Erickson-Viitanen S, Leopold L, Sandor V, Levy RS, Kantarjian HM, Verstovsek S.

J Hematol Oncol. 2013 Oct 29;6(1):81. doi: 10.1186/1756-8722-6-81.

9.

Combination treatment for myeloproliferative neoplasms using JAK and pan-class I PI3K inhibitors.

Choong ML, Pecquet C, Pendharkar V, Diaconu CC, Yong JW, Tai SJ, Wang SF, Defour JP, Sangthongpitag K, Villeval JL, Vainchenker W, Constantinescu SN, Lee MA.

J Cell Mol Med. 2013 Nov;17(11):1397-409. doi: 10.1111/jcmm.12156. Epub 2013 Nov 19.

10.

Comprehensive review of JAK inhibitors in myeloproliferative neoplasms.

Sonbol MB, Firwana B, Zarzour A, Morad M, Rana V, Tiu RV.

Ther Adv Hematol. 2013 Feb;4(1):15-35. doi: 10.1177/2040620712461047.

11.

Hope and fear for interferon: the receptor-centric outlook on the future of interferon therapy.

Fuchs SY.

J Interferon Cytokine Res. 2013 Apr;33(4):211-25. doi: 10.1089/jir.2012.0117. Review.

12.

The clinical benefit of ruxolitinib across patient subgroups: analysis of a placebo-controlled, Phase III study in patients with myelofibrosis.

Verstovsek S, Mesa RA, Gotlib J, Levy RS, Gupta V, DiPersio JF, Catalano JV, Deininger M, Miller C, Silver RT, Talpaz M, Winton EF, Harvey JH Jr, Arcasoy MO, Hexner E, Lyons RM, Paquette R, Raza A, Vaddi K, Erickson-Viitanen S, Sun W, Sandor V, Kantarjian HM.

Br J Haematol. 2013 May;161(4):508-16. doi: 10.1111/bjh.12274. Epub 2013 Mar 11.

13.

Effect of ruxolitinib therapy on myelofibrosis-related symptoms and other patient-reported outcomes in COMFORT-I: a randomized, double-blind, placebo-controlled trial.

Mesa RA, Gotlib J, Gupta V, Catalano JV, Deininger MW, Shields AL, Miller CB, Silver RT, Talpaz M, Winton EF, Harvey JH, Hare T, Erickson-Viitanen S, Sun W, Sandor V, Levy RS, Kantarjian HM, Verstovsek S.

J Clin Oncol. 2013 Apr 1;31(10):1285-92. doi: 10.1200/JCO.2012.44.4489. Epub 2013 Feb 19.

14.

JAK1 gene polymorphisms are associated with the outcomes of hepatitis B virus infection, but not with α interferon therapy response in a Han Chinese population.

Chen K, Min H, Wu X, Zhu X, Li Z, Li H, Liu Y.

Genet Test Mol Biomarkers. 2012 Oct;16(10):1206-10. doi: 10.1089/gtmb.2012.0141. Epub 2012 Aug 17.

15.

The novel tyrosine kinase inhibitor AKN-028 has significant antileukemic activity in cell lines and primary cultures of acute myeloid leukemia.

Eriksson A, Hermanson M, Wickström M, Lindhagen E, Ekholm C, Jenmalm Jensen A, Löthgren A, Lehmann F, Larsson R, Parrow V, Höglund M.

Blood Cancer J. 2012 Aug 3;2:e81. doi: 10.1038/bcj.2012.28.

16.

Biology and clinical management of myeloproliferative neoplasms and development of the JAK inhibitor ruxolitinib.

Mascarenhas J, Mughal TI, Verstovsek S.

Curr Med Chem. 2012;19(26):4399-413. Review.

17.

High accuracy mutation detection in leukemia on a selected panel of cancer genes.

Kalender Atak Z, De Keersmaecker K, Gianfelici V, Geerdens E, Vandepoel R, Pauwels D, Porcu M, Lahortiga I, Brys V, Dirks WG, Quentmeier H, Cloos J, Cuppens H, Uyttebroeck A, Vandenberghe P, Cools J, Aerts S.

PLoS One. 2012;7(6):e38463. doi: 10.1371/journal.pone.0038463. Epub 2012 Jun 4.

18.

A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis.

Verstovsek S, Mesa RA, Gotlib J, Levy RS, Gupta V, DiPersio JF, Catalano JV, Deininger M, Miller C, Silver RT, Talpaz M, Winton EF, Harvey JH Jr, Arcasoy MO, Hexner E, Lyons RM, Paquette R, Raza A, Vaddi K, Erickson-Viitanen S, Koumenis IL, Sun W, Sandor V, Kantarjian HM.

N Engl J Med. 2012 Mar 1;366(9):799-807. doi: 10.1056/NEJMoa1110557.

19.

A novel, highly sensitive and rapid allele-specific loop-mediated amplification assay for the detection of the JAK2V617F mutation in chronic myeloproliferative neoplasms.

Minnucci G, Amicarelli G, Salmoiraghi S, Spinelli O, Guinea Montalvo ML, Giussani U, Adlerstein D, Rambaldi A.

Haematologica. 2012 Sep;97(9):1394-400. doi: 10.3324/haematol.2011.056184. Epub 2012 Feb 7.

20.

A mechanism underlying NOTCH-induced and ubiquitin-mediated JAK3 degradation.

Wu W, Sun XH.

J Biol Chem. 2011 Dec 2;286(48):41153-62. doi: 10.1074/jbc.M111.273755. Epub 2011 Oct 3.

Items per page

Supplemental Content

Write to the Help Desk